

17 November 2015

iQnovate Ltd to acquire stake in creative agency

iQnovate Ltd, a member of the iQ Group Global, is proud to announce it has signed an Agreement in Principal to acquire 50 percent of creative agency, Emedia Creative Pty Ltd.

It has been further agreed that Emedia Creative will immediately, post acquisition, commence the process for listing on the ASX.

Emedia Creative is a creative media agency with over 20 years experience providing creative design services. Following the acquisition, it is intended that Emedia Creative will expand its offering by creating a new business unit specialised in life science and pharmaceutical marketing.

The addition of creative services dedicated to the pharma industry will complement and support the iQ Group Global's offerings more broadly, in particular working hand in hand with another FarmaForce Ltd – a pharmaceutical contract sales organisation recently listed on the ASX.

‘The biotech industry is evolving so rapidly that organic growth alone will not suffice for a business to lead its sector. An acquisition such as this one creates a partnership that provides a point of difference’, stated CEO of The iQ Group Global, Dr George Symmalis.

“A ground breaking, innovative business such as iQnovate, joining forces with an inspiring and creative media house like Emedia creative, will enable us to communicate the life sciences in a coherent and captivating manner.”

The Corporate Advisor for the acquisition is iQ3Corp. Ltd, and the financing has been structured by iQX Investments Ltd.

END

For further information:

Investors

iQ3Corp Investor Relations Team
Email: investor.relations@iq3corp.com
Phone: +61 2 8239 5400

Media

Angela Maher
Director, Marketing, Media & Communications
Email: angela.maher@theiqgroup.com.au
Mobile: +61 438 519 916

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Ltd

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.